Phenotyping and Target Expression Profiling of CD34⁺/CD38^- and CD34⁺/CD38⁺ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia.

ABSTRACT: Leukemic stem cells (LSCs) are an emerging target of curative anti-leukemia therapy. In acute lymphoblastic leukemia (ALL), LSCs frequently express CD34 and often lack CD38. However, little is known about markers and targets expressed in ALL LSCs. We have examined marker- and target expression profiles in CD34⁺/CD38^- LSCs in patients with Ph⁺ ALL (n = 22) and Ph^- ALL (n = 27) by multi-color flow cytometry and qPCR. ALL LSCs expressed CD19 (B4), CD44 (Pgp-1), CD123 (IL-3RA), and CD184 (CXCR4) in all patients tested. Moreover, in various subgroups of patients, LSCs also displayed CD20 (MS4A1) (10/41 = 24%), CD22 (12/20 = 60%), CD33 (Siglec-3) (20/48 = 42%), CD52 (CAMPATH-1) (17/40 = 43%), IL-1RAP (13/29 = 45%), and/or CD135 (FLT3) (4/20 = 20%). CD2

SUBMITTER: Blatt K 

PROVIDER: S-EPMC5994777 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature